Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom
Year: 2024
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Treatment options for pre-treated patients with metastatic triple-negative breast cancer (mTNBC) remain limited. This is the first study to assess the real-world safety and efficacy of sacituzumab govitecan (SG) in the UK. METHODS: Data was retrospectively collected from 16 tertiary UK cancer centres. Pts had a diagnosis of mTNBC, received at least two prior lines of treatment (with at least one being in the metastatic setting) and received at least one dose of SG. RESULTS: 132 pts were included. Median age was 56 years (28-91). All patients were ECOG performance status (PS) 0-3 (PS0; 39, PS1; 76, PS2; 16, PS3;1). 75% (99/132) of pts had visceral metastases including 18% (24/132) of pts with CNS disease. Median PFS (mPFS) was 5.2 months (95% CI 4.5-6.6) with a median OS (mOS) of 8.7 months (95% CI 6.8-NA). The most common adverse events (AEs) were fatigue (all grade; 82%, G3/4; 14%), neutropenia (all grade; 55%, G3/4; 29%), diarrhoea (all grade; 58%, G3/4, 15%), and nausea (all grade; 38%, G3/4; 3%). SG dose reduction was required in 54% of pts. CONCLUSION: This study supports significant anti-tumour activity in heavily pre-treated pts with mTNBC. Toxicity data aligns with clinical trial experience.
Source: British Journal of Cancer
Authors: Daire Hanna, Sophie Merrick, Aruni Ghose, Michael John Devlin, Dorothy D. Yang, Edward Phillips, Alicia Okines, Neha Chopra, Elisavet Papadimatraki, Kirsty Ross, Iain Macpherson, Zhuang Y. Boh, Caroline O. Michie, Angela Swampillai, Sunnia Gupta, Tim Robinson, Lewis Germain, Chris Twelves, Charlotte Atkinson, Apostolos Konstantis, Pippa Riddle, Nicola Cresti, Jay D. Naik, Annabel Borley, Amy Guppy, Peter Schmid, Melissa Phillips
Institutions: National Health Service, St Bartholomew's Hospital, Queen Mary University of London, Barts Health NHS Trust, Barts Cancer Institute, University College London Hospitals NHS Foundation Trust, Royal Marsden NHS Foundation Trust, Royal Free London NHS Foundation Trust, Beatson West of Scotland Cancer Centre, Edinburgh Cancer Research, University of Edinburgh, Guy's and St Thomas' NHS Foundation Trust, Bristol NHS Foundation Trust, Taunton & Somerset NHS Foundation Trust, Princess Alexandra Hospital NHS Trust, Chelsea and Westminster Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne Hospital, Harrogate and District NHS Foundation Trust, Velindre Cancer Centre, Mount Vernon Cancer Centre
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,990
OpenAlex ID: W4395074932